Penn Medicine New Horizons in Nephrology Glomerular Disease Webinar 2026
$15.00
Video Course · Nephrology · 2026
This focused webinar examines B-cell targeting in glomerular disease through 9 lectures — covering monoclonal antibodies for IgA nephropathy, lupus nephritis, and membranous nephropathy with mechanism-to-bedside case presentations.
-
9lectures
-
1.72 GBsize
-
2026year
- B-cell immunobiology and depletion monitoring
- Anti-CD20 and BAFF/APRIL inhibitor data across three diseases
- Case-based treatment decisions with real clinical scenarios
B-cell targeting in glomerular disease — from immunobiology to bedside therapy
B cells drive renal inflammation through antibody production, antigen presentation, and cytokine release — and monoclonal antibodies targeting these pathways have reshaped the treatment of IgA nephropathy, lupus nephritis, and membranous nephropathy. This Penn Medicine webinar delivers nine video lectures on B-cell targeting in glomerular disease, pairing mechanism-focused instruction with case presentations that walk through real treatment decisions at the bedside.
-
9lectures
-
1.72 GBsize
-
2026year
Inside this resource
B-cell immunobiology and depletion monitoring
The opening session establishes the immunologic foundation: how B cells mediate kidney injury through pathogenic autoantibodies and immune complex deposition, and which monitoring strategies track B-cell depletion and repopulation during therapy with anti-CD20 and anti-CD19 agents.
Targeting IgA nephropathy and lupus nephritis
Two dedicated lectures review efficacy data for rituximab, obinutuzumab, and emerging BAFF/APRIL inhibitors in IgA nephropathy and lupus nephritis. Case presentations demonstrate treatment selection for patients failing standard immunosuppression, including rituximab-resistant lupus nephritis requiring protocol escalation.
Membranous nephropathy and primary podocytopathy
A focused session addresses novel antigens and targeted interventions for membranous nephropathy and primary podocytopathy, including anti-PLA2R antibody monitoring thresholds and rituximab-based treatment protocols with long-term outcome data.
Interactive case-based learning
Three clinical scenarios walk through treatment decisions in real time: membranous nephropathy with persistently elevated anti-PLA2R titers, lupus nephritis requiring escalation after incomplete induction response, and IgA nephropathy with progressive proteinuria despite maximal RAAS blockade.
Who this serves
- Nephrologists — selecting B-cell directed therapies for complex glomerular diseases
- Clinical immunologists — understanding monoclonal antibody mechanisms in renal inflammation
Faculty & syllabus
Topics covered 9 sessions
- Physiology, Monitoring and Targeting the B-Cell Pathway
- B-cell Targeting in IgA Nephropathy
- B-cell Targeting in Lupus Nephritis
- B-cell Targeting in Membranous Nephropathy, Primary Podocytopathy
- Case Presentation 1 — Membranous Nephropathy
- Case Presentation 2 — Lupus Nephritis
- Case Presentation 3 — IgA Nephropathy
- Ask the Panel (×2)
Before you buy
How long is the webinar?
Nine lectures totalling approximately 3 hours of recorded instruction, plus downloadable slides.
Does this cover ANCA-associated vasculitis?
B-cell targeting in ANCA vasculitis is mentioned but not a primary focus — the course concentrates on IgA nephropathy, lupus nephritis, and membranous nephropathy.
The chart
| Format | Video Course (9 lectures + PDFs) |
|---|---|
| Duration | 1.72 GB total |
| Year | 2026 |
| Publisher | Penn Medicine |
| Department | Nephrology |
| Delivery | Instant download after checkout · lifetime re-access |
Verified original fileInstant downloadEncrypted checkout
5 reviews for Penn Medicine New Horizons in Nephrology Glomerular Disease Webinar 2026
Add a review
Related products
Nephrology
Nephrology
Nephrology
Nephrology
Rachel W. –
Short, intense, and clinically relevant. Exactly what I needed to update my approach to refractory glomerular diseases in 2026.
Tom H. –
Wished for more time on ANCA-associated vasculitis — it was mentioned briefly but not deeply covered. The IgA and lupus content was thorough.
Mark S. –
Good overview of rituximab protocols across different glomerular diseases. The BAFF/APRIL inhibitor data was cutting-edge and forward-looking.
Linda P. –
The case presentations made the immunology accessible. I now feel more confident discussing rituximab options with my glomerular disease patients.
Anna C. –
The membranous nephropathy cases were exceptionally well-taught. Anti-PLA2R monitoring finally makes clinical sense after this course.